| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
Department of Clinical Biochemistry, University Hospital of Aarhus, Aarhus Amtssygehus, T. Hansengade 2, DK-8000 Aarhus C, Denmark, 1 Steno Diabetes Center, Gentofte, Denmark, 2 Medical Department M and the Medical Research Laboratories, Aarhus University Hospital, Aarhus, Denmark and 3 Faculty of Health Science, University of Aarhus, Aarhus, Denmark
(Correspondence should be addressed to L M Rasmussen; Email: lmr{at}dadlnet.dk
Objective: The bone-related peptide osteoprotegerin (OPG) has recently been found in increased amounts in the vasculature in diabetes. It is produced by vascular smooth muscle and endothelial cells, and may be implicated in the development of vascular calcifications. OPG is present in the circulation, where increased amounts have been observed in patients with diabetes. In this study, we examined whether plasma OPG is associated with the glycaemic and vascular status of patients with type 1 diabetes.
Methods: Two gender-, age- and duration-comparable groups of type 1 diabetic patients either with (n = 199) or without (n = 192) signs of diabetic nephropathy were studied. Plasma OPG was determined by an ELISA.
Results: The plasma OPG concentration was significantly higher in patients with nephropathy than those without (3.11 (2.49–3.99) vs 2.57 (2.19–3.21) (median (interquartiles), ng/ml), P < 0.001). Plasma OPG correlated with haemoglobin A1c (HbA1c), systolic blood pressure and age in both groups and, in addition, with kidney function in the nephropathic group. These correlations remained significant in multivariate models. In addition, we found that plasma OPG concentrations were increased among patients with cardiovascular diseases (CVD), both in the normoalbuminuric and the nephropathic groups. The differences between nephropathic and normoalbuminuric, as well as subgroups with and without CVD, could largely be ascribed to changes in HbA1c, age, systolic blood pressure and creatinine.
Conclusion: OPG is associated with glycaemic control and CVD in patients with type 1 diabetes, compatible with the hypothesis that OPG is associated with the development of diabetic vascular complications.
This article has been cited by other articles:
|
|
 |
|
  E. M. Lewiecki Denosumab in postmenopausal osteoporosis: what the clinician needs to know Therapeutic Advances in Musculoskeletal Diseases, October 1, 2009; 1(1): 13 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Nybo and L. M Rasmussen The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review Eur. J. Endocrinol., November 1, 2008; 159(5): 603 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lorz, A. Benito-Martin, A. Boucherot, A. C. Ucero, M. P. Rastaldi, A. Henger, S. Armelloni, B. Santamaria, C. C. Berthier, M. Kretzler, et al. The Death Ligand TRAIL in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2008; 19(5): 904 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Morony, Y. Tintut, Z. Zhang, R. C. Cattley, G. Van, D. Dwyer, M. Stolina, P. J. Kostenuik, and L. L. Demer Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr( / ) Mice Circulation, January 22, 2008; 117(3): 411 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lawrie, E. Waterman, M. Southwood, D. Evans, J. Suntharalingam, S. Francis, D. Crossman, P. Croucher, N. Morrell, and C. Newman Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension Am. J. Pathol., January 1, 2008; 172(1): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Nellemann, L. C. Gormsen, J. Dollerup, O. Schmitz, C. E. Mogensen, L. M. Rasmussen, and S. Nielsen Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria Diabetes Care, December 1, 2007; 30(12): 3122 - 3124. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Omland, M. H. Drazner, T. Ueland, M. Abedin, S. A. Murphy, P. Aukrust, and J. A. de Lemos Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function Hypertension, June 1, 2007; 49(6): 1392 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Secchiero, F. Corallini, A. Pandolfi, A. Consoli, R. Candido, B. Fabris, C. Celeghini, S. Capitani, and G. Zauli An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction Am. J. Pathol., December 1, 2006; 169(6): 2236 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Shin, Y. G. Shin, and C. H. Chung Elevated Serum Osteoprotegerin Levels Are Associated With Vascular Endothelial Dysfunction in Type 2 Diabetes Diabetes Care, July 1, 2006; 29(7): 1664 - 1666. [Full Text] [PDF]
|
|
|
|
|
|
J. Hjelmesaeth, T. Ueland, A. Flyvbjerg, J. Bollerslev, T. Leivestad, T. Jenssen, T. K. Hansen, S. Thiel, S. Sagedal, J. Roislien, et al. Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1746 - 1754. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
